Göhring B, Riemann D, Rebmann U, Heynemann H, Schabel J, Langner J
Department of Urology, Martin Luther University, Halle, Germany.
Urol Res. 1996;24(5):297-303. doi: 10.1007/BF00304780.
After tumor nephrectomy, patients suffering from metastatic renal cell carcinoma (RCC) received interleukin-2 (IL-2), interferon (IFN)-alpha-2b and 5-fluorouracil (5-FU) in one to three treatment cycles over 8 weeks. Using flow cytometry, we investigated the immunophenotype of peripheral blood lymphocytes from 22 patients during therapy. In all patients, we found an increase in the absolute number of T lymphocytes, especially of the CD4 type, and in the number of HLA-DR+, CD25+ T cells and natural killer (NK) cells. The mean number of B cells did not increase during therapy. The numbers of CD4+, CD8+ and CD25+ T cells correlated significantly with the clinical response. In addition, we found that the pretherapeutic number of T lymphocytes and B cells but not of NK cells was significantly higher in patients with a therapy-induced clinical response. In conclusion, we describe the predictive value of the number of lymphocytes from peripheral blood for the efficiency of IL-2/IFN-alpha-2b therapy in combination with 5-FU in patients with metastatic renal cell carcinoma.
肾肿瘤切除术后，转移性肾细胞癌（RCC）患者在8周内接受了1至3个疗程的白细胞介素-2（IL-2）、干扰素（IFN）-α-2b和5-氟尿嘧啶（5-FU）治疗。我们使用流式细胞术研究了22例患者在治疗期间外周血淋巴细胞的免疫表型。在所有患者中，我们发现T淋巴细胞的绝对数量增加，尤其是CD4型，以及HLA-DR+、CD25+ T细胞和自然杀伤（NK）细胞的数量增加。治疗期间B细胞的平均数量没有增加。CD4+、CD8+和CD25+ T细胞的数量与临床反应显著相关。此外，我们发现治疗诱导的临床反应患者的治疗前T淋巴细胞和B细胞数量显著高于NK细胞。总之，我们描述了外周血淋巴细胞数量对转移性肾细胞癌患者IL-2/IFN-α-2b联合5-FU治疗疗效的预测价值。
